Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Total Liabilities
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has total liabilities worth CN¥631.40 Million CNY (≈ $92.39 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002773 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Total Liabilities Trend (2009–2025)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 002773 current and non-current assets.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BSP Financial Group Ltd
AU:BFL
|
Australia | AU$37.82 Billion |
|
Corporación Inmobiliaria Vesta, S.A.B de C.V.
NYSE:VTMX
|
USA | $2.03 Billion |
|
Zhejiang Shenghua Biok Biology Co Ltd
SHG:600226
|
China | CN¥1.24 Billion |
|
Eternal Materials Co Ltd
TW:1717
|
Taiwan | NT$32.05 Billion |
|
Sportradar Group AG
NASDAQ:SRAD
|
USA | $1.78 Billion |
|
Shufersal
TA:SAE
|
Israel | ILA11.23 Billion |
|
Ansell Limited
F:PD1A
|
Germany | €1.34 Billion |
|
CLARIANT ADR 1/SF 4
F:CLRS
|
Germany | €3.69 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002773 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Kanghong Pharmaceuticals Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
The table below shows the annual total liabilities of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥645.22 Million ≈ $94.42 Million |
-7.17% |
| 2024-12-31 | CN¥695.07 Million ≈ $101.71 Million |
-3.16% |
| 2023-12-31 | CN¥717.76 Million ≈ $105.03 Million |
-11.81% |
| 2022-12-31 | CN¥813.85 Million ≈ $119.09 Million |
-4.37% |
| 2021-12-31 | CN¥851.08 Million ≈ $124.54 Million |
-31.76% |
| 2020-12-31 | CN¥1.25 Billion ≈ $182.50 Million |
+3.37% |
| 2019-12-31 | CN¥1.21 Billion ≈ $176.54 Million |
+8.60% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.56 Million |
+6.54% |
| 2017-12-31 | CN¥1.04 Billion ≈ $152.58 Million |
+22.20% |
| 2016-12-31 | CN¥853.27 Million ≈ $124.86 Million |
+126.82% |
| 2015-12-31 | CN¥376.19 Million ≈ $55.05 Million |
+14.30% |
| 2014-12-31 | CN¥329.11 Million ≈ $48.16 Million |
+7.66% |
| 2013-12-31 | CN¥305.69 Million ≈ $44.73 Million |
-18.57% |
| 2012-12-31 | CN¥375.39 Million ≈ $54.93 Million |
+4.39% |
| 2011-12-31 | CN¥359.58 Million ≈ $52.62 Million |
-1.81% |
| 2010-12-31 | CN¥366.21 Million ≈ $53.59 Million |
+29.07% |
| 2009-12-31 | CN¥283.73 Million ≈ $41.52 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.